HC Wainwright Has Bearish Estimate for BrainsWay Q3 Earnings

BrainsWay Ltd. (NASDAQ:BWAY) – HC Wainwright lowered their Q3 2024 earnings per share (EPS) estimates for BrainsWay in a research report issued on Monday, October 21st. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.02 per share for the quarter, down from their previous forecast of $0.04. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for BrainsWay’s current full-year earnings is $0.06 per share. HC Wainwright also issued estimates for BrainsWay’s Q4 2024 earnings at $0.02 EPS and FY2024 earnings at $0.06 EPS.

Separately, Northland Securities lifted their price target on BrainsWay from $11.00 to $12.50 and gave the stock an “outperform” rating in a research note on Thursday, October 3rd.

BrainsWay Stock Down 0.2 %

Shares of BWAY stock opened at $9.92 on Tuesday. The business has a 50-day moving average price of $8.47 and a two-hundred day moving average price of $6.90. BrainsWay has a 12-month low of $3.09 and a 12-month high of $10.61. The firm has a market cap of $165.32 million, a P/E ratio of -110.22 and a beta of 1.26.

BrainsWay (NASDAQ:BWAY) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter. BrainsWay had a return on equity of 1.45% and a net margin of 1.67%. The firm had revenue of $10.01 million during the quarter, compared to analyst estimates of $9.40 million. During the same quarter in the previous year, the company posted ($0.05) earnings per share.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BWAY. Virtu Financial LLC purchased a new position in BrainsWay during the 1st quarter valued at about $60,000. Quadrature Capital Ltd purchased a new position in shares of BrainsWay during the 4th quarter worth approximately $70,000. Rhumbline Advisers grew its holdings in shares of BrainsWay by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock worth $110,000 after acquiring an additional 1,695 shares during the period. Perritt Capital Management Inc purchased a new position in shares of BrainsWay during the 2nd quarter worth approximately $121,000. Finally, Good Life Advisors LLC grew its holdings in shares of BrainsWay by 65.5% during the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock worth $516,000 after acquiring an additional 22,080 shares during the period. Hedge funds and other institutional investors own 30.11% of the company’s stock.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.